Double-digit growth, an expanding staff and near-completion of stylish new office digs all made for a gratifying year at Surge Worldwide Healthcare Communications, president Carleen Kelly says. In recent months, Surge has continued to handle global duties for Schering-Plough's Nasonex and global brand initiatives for Schering-Plough and Merck's jointly marketed cholesterol drugs Vytorin/Inegy and Zetia/Ezetrol. Among the agency's challenges are managing new business and identifying and retaining top talent. As Surge enjoys its success, the agency's staff is cognizant that the potential always exists for bumps in the road. Despite the challenges that may or may not lie ahead, Kelly says it remains her agency's duty to offer guidance as well as insure really good messaging for its clients and brands.